Long-term oral propafenone therapy for suppression of refractory symptomatic atrial fibrillation and atrial flutter

Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts 02115.

Sixty patients who had recurrent episodes of symptomatic atrial fibrillation or flutter, or both, and who had failed one to five prior drug trials were treated with open label oral propafenone hydrochloride. On a mean maximal tolerated dose of 795 +/- 180 mg/day, actuarial estimates of the percent of individuals free of recurrences of symptomatic atrial fibrillation/flutter during propafenone treatment were: 1 month, 54%; 3 months, 44% and 6 months, 40%. No individual baseline characteristic achieved statistical significance as a correlate of poor response to propafenone. Drug-related adverse reactions were reported in 22% of patients but were severe enough to require termination of propafenone in only 5%. Thus, oral propafenone is a useful and well tolerated drug for long-term suppression of symptomatic recurrences of atrial fibrillation/flutter despite a history of unresponsiveness to prior antiarrhythmic drug treatment.

This article has been cited by other articles:

				A. Da Costa, J. Thevenin, F. Roche, C. Romeyer-Bouchard, L. Abdellaoui, M. Messier, L. Denis, E. Faure, R. Gonthier, G. Kruszynski, et al. Results From the Loire-Ardeche-Drome-Isere-Puy-de-Dome (LADIP) Trial on Atrial Flutter, a Multicentric Prospective Randomized Study Comparing Amiodarone and Radiofrequency Ablation After the First Episode of Symptomatic Atrial Flutter Circulation, October 17, 2006; 114(16): 1676 - 1681. [Abstract] [Full Text] [PDF]

				Writing Committee Members, V. Fuster, L. E. Ryden, D. S. Cannom, H. J. Crijns, A. B. Curtis, K. A. Ellenbogen, J. L. Halperin, J.-Y. Le Heuzey, G. N. Kay, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: full text: A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation) Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society Europace, September 1, 2006; 8(9): 651 - 745. [Full Text] [PDF]

				V. Fuster, L. E. Ryden, D. S. Cannom, H. J. Crijns, A. B. Curtis, K. A. Ellenbogen, J. L. Halperin, J.-Y. Le Heuzey, G. N. Kay, J. E. Lowe, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation) Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society J. Am. Coll. Cardiol., August 15, 2006; 48(4): e149 - e246. [Full Text] [PDF]

				V. Fuster, L. E. Ryden, D. S. Cannom, H. J. Crijns, A. B. Curtis, K. A. Ellenbogen, J. L. Halperin, J.-Y. Le Heuzey, G. N. Kay, J. E. Lowe, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society Circulation, August 15, 2006; 114(7): e257 - e354. [Full Text] [PDF]

				M. Gulizia, S. Mangiameli, G. Chiaranda, V. Spadola, N. Di Giovanni, A. Colletti, V. Bulla, A. Circo, O. Pensabene, L. Vasquez, et al. Design and rationale of a randomized study to compare amiodarone and Class IC anti-arrhythmic drugs in terms of atrial fibrillation treatment efficacy in patients paced for sinus node disease: the PITAGORA trial. Europace, April 1, 2006; 8(4): 302 - 305. [Abstract] [Full Text] [PDF]

				S. Saksena, A. Prakash, P. Ziegler, J. D. Hummel, P. Friedman, V. J. Plumb, D. G. Wyse, E. Johnson, S. Fitts, R. Mehra, et al. Improved suppression of recurrent atrial fibrillation with dual-site right atrial pacing and antiarrhythmic drug therapy J. Am. Coll. Cardiol., September 18, 2002; 40(6): 1140 - 1150. [Abstract] [Full Text] [PDF]

				M. Sami Are we ready for dual-site right atrial pacing? J. Am. Coll. Cardiol., September 18, 2002; 40(6): 1151 - 1152. [Full Text] [PDF]

				Guidelines for the management of patients with atrial fibrillation. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to develop guidelines for the management of patients with atrial fibrillation) developed in collaboration with the North American Society of Pacing and Electrophysiology Eur. Heart J., October 2, 2001; 22(20): 1852 - 1923. [PDF]

				V. Fuster, L. E. Ryden, R. W. Asinger, D. S. Cannom, H. J. Crijns, R. L. Frye, J. L. Halperin, G. N. Kay, W. W. Klein, S. Levy, et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation) Developed in Collaboration With the North American Society of Pacing and Electrophysiology J. Am. Coll. Cardiol., October 1, 2001; 38(4): 1266 - 1266. [Full Text] [PDF]

				D. Roy, M. Talajic, P. Dorian, S. Connolly, M. J. Eisenberg, M. Green, T. Kus, J. Lambert, M. Dubuc, P. Gagne, et al. Amiodarone to Prevent Recurrence of Atrial Fibrillation N. Engl. J. Med., March 30, 2000; 342(13): 913 - 920. [Abstract] [Full Text] [PDF]

				W.-C. Yu, S.-H. Lee, C.-T. Tai, C.-F. Tsai, M.-H. Hsieh, C.-C. Chen, Y.-A. Ding, M.-S. Chang, and S.-A. Chen Reversal of atrial electrical remodeling following cardioversion of long-standing atrial fibrillation in man Cardiovasc Res, May 1, 1999; 42(2): 470 - 476. [Abstract] [Full Text] [PDF]

				M. Valderrabano and B. N. Singh Review : Electrophysiologic and Antiarrhythmic Effects of Propafenone: Focus on Atrial Fibrillation Journal of Cardiovascular Pharmacology and Therapeutics, January 1, 1999; 4(3): 183 - 198. [PDF]

				C.J. Meurling, M.P. Ingemansson, A. Roijer, J. Carlson, C.J. Lindholm, B. Smideberg, L. Sorno, M. Stridh, and S.B. Olsson Attenuation of electrical remodelling in chronic atrial fibrillation following oral treatment with verapamil Europace, January 1, 1999; 1(4): 234 - 241. [Abstract] [PDF]

				E. G. Daoud, F. Bogun, R. Goyal, M. Harvey, K. C. Man, S. A. Strickberger, and F. Morady Effect of Atrial Fibrillation on Atrial Refractoriness in Humans Circulation, October 1, 1996; 94(7): 1600 - 1606. [Abstract] [Full Text]

				E. N. Prystowsky, D. W. Benson Jr, V. Fuster, R. G. Hart, G. N. Kay, R. J. Myerburg, G. V. Naccarelli, and D. G. Wyse Management of Patients With Atrial Fibrillation : A Statement for Healthcare Professionals From the Subcommittee on Electrocardiography and Electrophysiology, American Heart Association Circulation, March 15, 1996; 93(6): 1262 - 1277. [Full Text]

				A. T. M. Gosselink, H. J. G. M. Crijns, I. C. Van Gelder, H. Hillige, A. C. P. Wiesfeld, and K. I. Lie Low-Dose Amiodarone for Maintenance of Sinus Rhythm After Cardioversion of Atrial Fibrillation or Flutter JAMA, June 24, 1992; 267(24): 3289 - 3293. [Abstract] [PDF]

				E. L.C. Pritchett, E. A. McCarthy, and W. E. Wilkinson Propafenone Treatment of Symptomatic Paroxysmal Supraventricular Arrhythmias: A Randomized, Placebo-Controlled, Crossover Trial in Patients Tolerating Oral Therapy Ann Intern Med, April 1, 1991; 114(7): 539 - 544. [Abstract] [PDF]

				PROMISING NEW THERAPY FOR ATRIAL ARRHYTHMIAS Journal Watch (General), October 7, 1988; 1988(1007): 2 - 2. [Full Text]